Navigation Links
Mirixa Debuts New Clinical Technology Solutions for Enhancing Patient Care
Date:9/17/2007

MirixaPro 2.2 enables the next generation in medication therapy management

and medication adherence services

RESTON, Va., Sept. 17 /PRNewswire/ -- Mirixa Corporation, a leading developer of innovative clinical solutions that facilitate pharmacist-based patient care services, today announced the immediate availability of version 2.2 of the MirixaPro(TM) product suite (MirixaPro 2.2). With this latest release of MirixaPro, pharmacies nationwide have fingertip access to an enhanced array of clinical care management tools that streamline pharmacy-based delivery of targeted patient care services including medication therapy management (MTM), medication adherence and disease management.

Leveraging Mirixa's technology, pharmacists have delivered tens of thousands of targeted MTM patient interventions, resolved thousands of alerts indicating potential safety issues and worked actively with patients and physicians to improve medication-related care. Qualifying patient cases are delivered directly and securely to the pharmacist, along with the patient's medication history. MirixaPro's workflow system supports delivery of multiple interventions through a single Web-based interface.

"Medication non-adherence and inadequate medication management is nothing short of a national epidemic," says Eric Zimmerman, Chief Innovation Officer and General Manager of Mirixa Clinical. "About 50% of patients with chronic conditions do not take their medications correctly -- we can and must do far better. At Mirixa, we're convinced the solution starts by levering the 'triangle of trust' between patients, physicians and pharmacists.

"MirixaPro makes collaboration easier by using data to pinpoint care improvement opportunities, monitor progress, and speed the flow of information across a secure network of care. The results so far are encouraging -- every day we hear from pharmacists using our technologies to collaborate with physicians to close gaps in care, resolve safety risks, and help consumers become confident and successful in managing their health," added Zimmerman.

MirixaPro 2.2 will be previewed by industry leaders at the Health 2.0 Conference on September 20 in San Francisco, CA as well as at the NACDS Medication Therapy Management Services in Community Pharmacy Conference September 19-20 in Philadelphia, PA.

About Mirixa

Mirixa Corporation is a leading developer of innovative clinical solutions that facilitate pharmacist-based patient care services and a leader in Medication Therapy Management (MTM) technology solutions. Founded by the National Community Pharmacists Association (NCPA), Mirixa has assembled the largest pharmacy services network of its kind with over 40,000 contracted community pharmacies -- including both independents and chains. Mirixa's technology portfolio empowers the delivery of highly targeted medication management programs, patient education, recruitment campaigns and patient medication records. The company's leadership team shares a vision and passion for improving patient care, reducing overall health costs, and expanding consumer access to accurate medication information. Mirixa is headquartered in the heart of the Dulles Technology Corridor in Reston, VA; with offices in California, Texas and New Jersey. For more information visit http://www.Mirixa.com.

Contact: Liz Deakin

Mirixa Corporation

Phone: 703-600-1226

E-mail: ldeakin@mirixa.com


'/>"/>
SOURCE Mirixa Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. How do patients benefit of clinical trials
2. Magnetic resonance angiography in clinical medicine
3. Clinical trials need to be more frank
4. AEternas acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy
5. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
6. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
7. Clinical Comparisons Between ADHD Drugs Are Less
8. Outsourcing clinical trials to India
9. Erectile dysfunction: an early warning sign of clinically silent coronary artery disease?
10. India to maintain Public domain Registry database of clinical trials conducted in India.
11. A Novel System For Clinical Banking Of Umbilical Cord Blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... Goodcents Deli Fresh Subs ... the Lincoln, Neb. area this year. , The first new location will open ... location will open at 84th and Northern Lights Drive this fall. And the third ...
(Date:4/27/2017)... ... ... Are you investing in the safety of your friends and family? Each year, ... most of us assume this type of accident will never happen to us, the ... the time to learn how to respond effectively or prevent these accidents from occurring ...
(Date:4/26/2017)... ... 26, 2017 , ... Jump Technologies, Inc., an innovative software ... completed a round of funding to accelerate its growth strategies. The $3.5 million ... is a growth equity firm focused on investments in healthcare and technology companies. ...
(Date:4/26/2017)... ... April 26, 2017 , ... Journal of Oral Implantology – Tooth ... to overall dental health, including complications with speech, eating, and overcompensation of mouth due ... replace lost teeth. As the number of tooth replacements increase, it is imperative to ...
(Date:4/26/2017)... ... April 26, 2017 , ... CareSet Labs ... of e-prescribing as measured in Part D Medicare data. The dataset, called PaPR ... either using e-prescribing, faxes or paper. The PaPR (pronounced "paper") data set ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... -- Research and Markets has announced the ... Prospects: Addressing Production Complexities Through Risk Management and Quality ... ... and Market Prospects: Overcoming Production Complexities Through Risk Management ... the current trends in the global biosimilars market, with ...
(Date:4/20/2017)... Inc ., a digital health company focused on modernizing and ... $25 million in Series B funding led by Qiming US ... Seattle that is part of a broader family ... included participation from SR One , who led ZappRx,s ... Google Ventures). As part of the financing, Mark McDade ...
(Date:4/20/2017)... , April 20, 2017 NeuroVive Pharmaceutical ... today announced positive preclinical results demonstrating anti-fibrotic ... for non-alcoholic steatohepatitis (NASH), in an additional ... NV556 has previously shown similar anti-fibrotic ... Today, NeuroVive,s scientists present novel data demonstrating ...
Breaking Medicine Technology: